Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)
This study tests whether personalized treatments using targeted drugs called antibody-drug conjugates can help patients with advanced solid tumors. It looks at specific proteins on cancer cells to match each patient with the medication that is most likely to attack their specific tumor.
You may be able to join if you have an advanced or metastatic solid tumor that has not responded well to standard treatments or has no standard treatment options left. Your tumor will be tested for specific proteins like Trop-2, nectin-4, or HER2 to see which study medicine is right for you.
You will undergo tissue and blood tests, imaging scans like CT or MRI, and heart function checks to see if you qualify and to monitor your health. Depending on your test results, you will receive one of the targeted study medications designed to home in on your cancer cells.
This study is currently recruiting participants at locations in California, United States. Your care team will guide you through the exact steps and visit schedules at your nearest study site.
- 1Tests personalized treatments matched to your tumor's specific protein profile.
- 2Uses targeted medications designed to deliver cancer-killing drugs directly to tumor cells.
- 3Currently recruiting participants with advanced solid tumors at select locations in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.